Meanwhile, our study strongly suggests the effectiveness of UFSHR, a novel analog of YM155, as an option to target survivin in order to control aggressive phenotypes in pancreatic tumor cells. This evidence concerns the gene BIRC5 and pancreatic neoplasm.